Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNK3 | O14649 | 8/20 | 0.58 |
| ▸ | KCNK9 | Q9NPC2 | 7/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.54 |
| ▸ | MEN1 | O00255 | 3/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 4/20 | 0.52 |
| ▸ | POLB | P06746 | 2/20 | 0.52 |
| ▸ | NPC1 | O15118 | 3/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.51 |
| ▸ | CA1 | P00915 | 1/20 | 0.51 |
| ▸ | CA2 | P00918 | 1/20 | 0.51 |
| ▸ | CA9 | Q16790 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14568092 | 0.92 | HDAC1 (0.52) | KCNK3KCNK9KMT2AMEN1TP53 | |
| SCHEMBL11987744 | 0.90 | CA1 (0.52) | KCNK3KCNK9KMT2AMEN1TP53 | |
| SCHEMBL18343191 | 0.88 | KCNK3 (0.57) | KCNK3KCNK9KMT2AMEN1RAB9A | |
| SCHEMBL104107 | 0.87 | KCNK9 (0.60) | KCNK3KCNK9KMT2AMEN1TP53 | |
| SCHEMBL1329990 | 0.87 | KMT2A (0.58) | KCNK3KCNK9KMT2AMEN1TP53 | |
| SCHEMBL31224630 | 0.86 | RAB9A (0.50) | KCNK3KCNK9KMT2AMEN1TP53 | |
| SCHEMBL24628621 | 0.86 | MEN1 (0.50) | KCNK3KCNK9KMT2AMEN1TP53 | |
| SCHEMBL18343409 | 0.86 | KCNK3 (0.61) | KCNK3KMT2AMEN1TP53RAB9A | |
| SCHEMBL5675377 | 0.86 | PDGFRB (0.58) | KMT2AMEN1TP53SIRT1RAB9A | |
| SCHEMBL7139795 | 0.86 | CA1 (0.48) | KCNK3KCNK9KMT2AMEN1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011101640-A1 | FUSED HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF MALARIA | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2011-08-25 | — | — | WO | disclosed |
| US-20070054916-A1 | Aryl nitrogen-containing bicyclic compounds and methods of use | AMGEN INC. | 2007-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070054916-A1 | Aryl nitrogen-containing bicyclic compounds and methods of use | MAP3K1, MAP3K5, MAP3K2 | KCNK3 835/4885KCNK9 2067/4885KMT2A 1204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.